FDA issues final guidance for psychedelic drug development and schedules a September public hearing on the future of psychedelic therapies

FDA psychedelic guidance now sets the agency's current expectations for developing psychedelic drugs, while a September public hearing opens a broader discussion about how psychedelic therapies should be studied, reviewed, and integrated into medicine. The guidance focuses on clinical development issues such as trial design, safety monitoring, functional unblinding, psychotherapy support, and the challenges of measuring outcomes when intense subjective effects can shape participant and investigator expectations. The hearing signals that regulators are not only refining technical drug-development standards but also gathering public input on the wider therapeutic model around these treatments. MDMA- and psilocybin-based programs sit closest to this regulatory crossroads because both have driven much of the modern evidence base and commercial pipeline. FDA's actions matter because clearer rules can shape investor confidence, sponsor strategy, and the timeline for whether psychedelic-assisted therapies move from experimental settings into approved clinical care.